Health Care & Life Sciences » Pharmaceuticals | Siegfried Holding AG

Siegfried Holding AG | Income Statement

Fiscal year is January-December. All values CHF Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
374,940.00
315,282.00
480,571.00
717,729.00
750,468.00
794,297
Cost of Goods Sold (COGS) incl. D&A
276,192.00
242,517.00
389,919.00
608,509.00
611,658.00
637,969
Gross Income
98,748.00
72,765.00
90,652.00
109,220.00
138,810.00
156,328
SG&A Expense
67,170.00
46,625.00
59,641.00
61,209.00
80,490.00
86,943
EBIT
31,578.00
26,140.00
31,011.00
50,311.00
61,120.00
72,685
Unusual Expense
100.00
300.00
8,100.00
7,500.00
-
-
Non Operating Income/Expense
9,684.00
7,417.00
3,237.00
267.00
1,140.00
904
Interest Expense
2,800.00
2,200.00
5,500.00
7,800.00
3,700.00
3,461
Pretax Income
50,256.00
31,786.00
37,051.00
34,733.00
56,307.00
70,202
Income Tax
3,595.00
6,770.00
2,049.00
6,827.00
16,575.00
13,854
Consolidated Net Income
53,851.00
38,556.00
39,100.00
27,906.00
39,732.00
56,310
Net Income
53,851.00
38,556.00
39,100.00
27,906.00
39,732.00
56,310
Net Income After Extraordinaries
53,851.00
38,556.00
39,100.00
27,906.00
39,732.00
56,310
Net Income Available to Common
53,851.00
38,556.00
39,100.00
27,906.00
39,732.00
56,310
EPS (Basic)
15.07
9.97
9.89
7.18
10.01
13.52
Basic Shares Outstanding
3,572.40
3,868.40
3,953.50
3,885.60
3,969.20
4,164.10
EPS (Diluted)
13.73
9.92
9.76
7.04
9.71
13.10
Diluted Shares Outstanding
3,922.40
3,886.60
4,006.90
3,965.20
4,092.90
4,297.40
EBITDA
56,381.00
50,930.00
64,692.00
100,309.00
110,494.00
122,492
Other Operating Expense
-
-
-
2,300.00
2,800.00
3,300
Non-Operating Interest Income
11,300.00
171.00
236.00
25.00
35.00
74
Equity in Affiliates (Pretax)
594.00
42.00
33.00
36.00
8.00
-

About Siegfried Holding

View Profile
Address
Untere Brühlstrasse 4
Zofingen Aargau (Argovia) 4800
Switzerland
Employees -
Website http://www.siegfried.ch
Updated 07/08/2019
Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. It also provides development and production services for finished dosage forms including sterile filling. The company was founded by Samuel Benoni Siegfried in 1873 and is headquartered in Zofingen, Switzerland.